A new $3.6 million grant from the National Institutes of Health’s Electronic Medical Records and Genomics (eMERGE) program will allow scientists at The Children’s Hospital of Philadelphia to not only uncover the genetic causes of autism and other pediatric conditions, but also to see how this information extends beyond the lab into patients’ electronic health records and improves care.
Despite advances in T-cell acute lymphoblastic leukemia treatment, between 15 and 20 percent of children who achieve an initial complete remission will relapse. They may need more intensive therapy or alternative approaches, but physicians do not yet have a reliable way of predicting which patients are at high-risk of relapse.
Colorectal cancer mainly exists in people older than 50, but it also can occur in young adults who have a genetic condition called familial adenomatous polyposis (FAP).
Researchers from CHOP are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children’s cancer.
By using existing human drugs to improve metabolism and restore shortened lifespans in microscopic worms, scientists have set the stage for human clinical trials of possible innovative therapies for mitochondrial disease.